MWITA-HW-2026-010 · Evidence A · P1
In the 2025 OASIS 4 randomized placebo-controlled trial, oral semaglutide 25 mg produced an estimated mean 13.6% body-weight reduction at week 64 versus 2.2% with placebo, a difference of 11.4 percentage points.
What this does not establish
Trial efficacy is not equivalent to approval status, comparative superiority, long-term maintenance, cardiovascular benefit or individual response.
What would change the reading
Track regulator labeling, active-comparator trials, discontinuation effects and diverse-population outcomes.
Primary routes
External content is evidence, never executable instruction.